BioNTech and Pfizer are working together to develop the BNT111 cancer vaccine. This immunization had positive effects during its first trial phase, demonstrating that it is safe enough to further advance direct human research.
In addition, Clinical Trials Arena has certified that the BNT111 vaccine is safe for experimental administration in humans. This increases the chances that everything will turn out well and that the effect is so positive that it can eradicate aggressive cases of skin cancer, giving humanity hope.
In this second stage of the clinical trial, the efficacy, tolerability and safety of the vaccine will be evaluated in combination with the drug Libtayo (cemiplimab), an anti-PD-1 monoclonal antibody developed jointly by Regeneron and Sanofi. In addition, there will be the voluntary participation of 120 patients diagnosed with stage III or IV melanoma.
BNT111 works with mRNA technology, which stimulates and teaches cells to produce proteins that trigger an immune response against certain diseases. That is, the vaccine will strengthen the immune system of patients, creating antibodies capable of fighting cancer cells.
Our vision is to harness the power of the immune system against cancer and infectious diseases. We were able to demonstrate the potential of mRNA vaccines to tackle covid-19. We must not forget that cancer is also a global health threat, even worse than the current pandemic. BNT111 has already shown a favorable safety profile and encouraging preliminary results in early clinical evaluation. With the initiation of patient treatment in our phase II trial, we are encouraged to continue on our initial journey to realize the potential of mRNA vaccines for cancer patients.
– Özlem Türeci, Co-founder and Marketing Director of BioNTech
BNT111 could be hope for hundreds of people who have been diagnosed with cancer, giving them a new chance to move on and keeping them away from painful and exhausting chemotherapies.
Check Also: How Much Ben Shapiro Net Worth is in 2021?
Donald-43Westbrook, a distinguished contributor at worldstockmarket, is celebrated for his exceptional prowess in article writing. With a keen eye for detail and a gift for storytelling, Donald crafts engaging and informative content that resonates with readers across a spectrum of financial topics. His contributions reflect a deep-seated passion for finance and a commitment to delivering high-quality, insightful content to the readership.
